ArticleJournal of inflammation research2021
Novel 1,3,4-Oxadiazole Derivatives of Pyrrolo[3,4-
Article in Journal of inflammation research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 21 citations in OpenAlex.
- Molecularly diverse lonazolac-inspired pyrazole-cyanopyridin-2-one conjugates: design, synthesis, in vitro, in vivo and in silico studies as multi-target anti-inflammatory agents.Molecular diversity · 2026Article
- The Synergy of Macrocycles and Heterocycles: A Review of Coordination Behavior, Sensing, and Functional Materials Based on Calixarenes.Molecules (Basel, Switzerland) · 2026Review
- 1,3,4-Oxadiazole Derivatives of Pyrrolo[3,4-Pharmaceuticals (Basel, Switzerland) · 2025Article
- Hepatoprotective, anti-inflammatory, and wound healing effects of spirulina in rats.Journal of advanced veterinary and animal research · 2025Article
- The Improvement of Intestinal Mucosal Epithelial Barrier Integrity by 1,3,4-Oxadiazole Derivatives of Pyrrolo[3,4-Journal of inflammation research · 2025Article
- Design, Synthesis, and Biological Evaluation of Novel Phenoxy Acetic Acid Derivatives as Selective COX-2 Inhibitors Coupled with Comprehensive Bio-Pharmacological Inquiry, Histopathological Profiling, and Toxicological Scrutiny.Molecules (Basel, Switzerland) · 2024Article
- Anti-Inflammatory and Antioxidant Pyrrolo[3,4-International journal of molecular sciences · 2024Article
- Synthesis, Biological, Spectroscopic and Computational Investigations of NovelMolecules (Basel, Switzerland) · 2023Article
- Article
- Interactions ofMembranes · 2023Article
- Targeting Lineage-Specific Transcription Factors and Cytokines of the Th17/Treg Axis by Novel 1,3,4-Oxadiazole Derivatives of Pyrrolo[3,4-International journal of molecular sciences · 2022Article
- Exploring the Antiparasitic Activity ofMolecules (Basel, Switzerland) · 2022Article
- Sanguinarine-Chelerythrine Fraction ofOxidative medicine and cellular longevity · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background and purposeDue to the risk of gastrointestinal damage and various tissue toxicity associated with non-steroidal anti-inflammatory drugs (NSAIDs) use, investigating new anti-inflammatory agents with efficacy comparable to that of NSAIDs but reduced toxicity is still a major challenge and a clinical need. Based on our previous study, new 1,3,4-oxadiazole derivatives of pyrrolo[3,4-
methodsThe anti-inflammatory effect of compounds
resultsPretreatment with both novel derivatives at 10 mg/kg and 20 mg/kg doses reduced paw edema, counteracted the increased PGE
conclusionNew compounds exert an anti-inflammatory effect, presumably via inhibiting inflammatory mediators release and inflammatory cell infiltration. Moreover, both possess a more favorable benefit-risk profile than indomethacin, especially compound
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.